(CLX)

Reporting relationship: Director
Issuer ticker: CLX
Reported as of: 30 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2026, 16:16:14 UTC
Prior SEC filing: 03 Sep 2026
Next SEC filing: 02 Oct 2026
Source filing: View source filing
Reporting owner signature: By Jinho Joo, Attorney-in-Fact

Key filing fact

Pierre R. Breber filed Form 4 for CLOROX CO /DE/ (CLX) on 02 Oct 2026.

Key facts

This page summarizes Pierre R. Breber's Form 4 filing for CLOROX CO /DE/ (CLX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Oct 2026, 16:16.

Change

Previous filing in this sequence was filed on 03 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001594960 Primary reporting owner

Breber Pierre R

Relationship: Director
Address: 1221 BROADWAY, OAKLAND
Signature: By Jinho Joo, Attorney-in-Fact
Signature date: 02 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 18,000
Date: 30 Sep 2026
Ownership: By Trust
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLX transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +43
Change %: +1.2%
Price: $0.000000^*
Shares after: 3,538
Date: 28 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 43
Exercise price
Footnotes: F2, F3, F4

CLX transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +417
Change %: +12%
Price: $0.000000^*
Shares after: 3,955
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 417
Exercise price
Footnotes: F2, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Indirectly owned through family trust.

Footnote F2

1-for-1

Footnote F3

Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan.

Footnote F4

The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director.

Footnote F5

Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.